A practical guide to basal and prandial insulin therapy - PubMed (original) (raw)
A practical guide to basal and prandial insulin therapy
R R Holman et al. Diabet Med. 1985 Jan.
Abstract
Separating basal and meal-related insulin requirements allows a systematic approach to subcutaneous insulin therapy. Simple guidelines for both the doctor and patient can cater for the spectrum of severity of diabetes. A non-insulin-dependent diabetic who, despite dieting, continues to have moderate fasting hyperglycaemia (6-10 mmol/l) may need only a basal insulin supplement, whereas a totally insulin-dependent diabetic usually needs similar amounts of basal and meal-related insulin. The likely insulin requirements of individual diabetics can be predicted, including the increased amounts required by obese patients. The algorithms have been developed using ultralente to provide the basal insulin requirement, but the principles and doses probably apply to other similarly long-acting insulins or an insulin pump. The insulin doses can be easily altered for varying lifestyles, including night work, religious fasts or long distance aeroplane travel, and for temporary disturbances such as operations or intercurrent infections.
Similar articles
- Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T. Kawamori R, et al. Diabetes Care. 1989 Nov-Dec;12(10):680-5. doi: 10.2337/diacare.12.10.680. Diabetes Care. 1989. PMID: 2515048 - Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Rabasa-Lhoret R, et al. Diabetes Care. 1999 May;22(5):667-73. doi: 10.2337/diacare.22.5.667. Diabetes Care. 1999. PMID: 10332663 Clinical Trial. - Basal-prandial insulin therapy: Scientific concept review and application.
Leahy JL. Leahy JL. Am J Med Sci. 2006 Jul;332(1):24-31. doi: 10.1097/00000441-200607000-00005. Am J Med Sci. 2006. PMID: 16845238 Review. - Novel insulins: expanding options in diabetes management.
Gerich JE. Gerich JE. Am J Med. 2002 Sep;113(4):308-16. doi: 10.1016/s0002-9343(02)01176-2. Am J Med. 2002. PMID: 12361817 Review.
Cited by
- UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
[No authors listed] [No authors listed] Diabetologia. 1991 Dec;34(12):877-90. Diabetologia. 1991. PMID: 1778353 Clinical Trial. - Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial.
Lawton J, Jenkins N, Darbyshire JL, Holman RR, Farmer AJ, Hallowell N. Lawton J, et al. Trials. 2011 May 4;12:108. doi: 10.1186/1745-6215-12-108. Trials. 2011. PMID: 21542916 Free PMC article. Clinical Trial. - Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes.
Strange P. Strange P. J Diabetes Sci Technol. 2007 Jul;1(4):540-8. doi: 10.1177/193229680700100412. J Diabetes Sci Technol. 2007. PMID: 19885117 Free PMC article. - Insulin for the non-insulin dependent?
Holman RR. Holman RR. Br Med J (Clin Res Ed). 1988 May 21;296(6634):1469-70. doi: 10.1136/bmj.296.6634.1469-c. Br Med J (Clin Res Ed). 1988. PMID: 3132300 Free PMC article. No abstract available. - Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.
Filipova E, Uzunova K, Kalinov K, Vekov T. Filipova E, et al. Diabetes Ther. 2017 Aug;8(4):705-726. doi: 10.1007/s13300-017-0273-4. Epub 2017 Jun 16. Diabetes Ther. 2017. PMID: 28623552 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical